Research Community Events

Invited Guest Lecturers


Thales Papagiannakopoulos, PhD
‘Novel CRISPR/Cas9-based precision medicine approaches in lung cancer research’
Assistant Professor
Department of Pathology
New York University School of Medicine

Brendon M. Stiles MD
‘The ART of lung cancer immune evasion’
Associate Professor
Cardiothoracic Surgery
Weill Cornell Medical College, Cornell University

Monte Winslow, PhD
‘Molecular Determinants of Lung Cancer Growth and Metastasis’
Assistant Professor
Department of Genetics
Department of Pathology
Stanford University School of Medicine

Ray Osarogiagbon, MD
Director, Multidisciplinary Thoracic Oncology Program
Research Professor
Baptist Centers for Cancer Care


Jonathan M. Kurie, M.D
‘Transcriptional control of Golgi functions in tumor cells drives EMT and metastasis’
Professor, Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center, Houston, TX

Lauren Averett Byers, MD
Targeting the proteome in Small Cell Lung Cancer - Emergence of PARP, CHK1, and other DDR inhibitors’
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center, Houston, TX

Paul Bunn, MD
’Rational combinations for upfront EGFR mutant lung adenocarcinomas’
Professor, Division of Medical Oncology
James Dudley Chair in Lung Cancer Research
University of Colorado

Alice Shaw, MD, PhD
Director, Center for Thoracic Cancers, Massachusetts General Hospital
Paula O’Keeffe Endowed Chair in Thoracic Oncology, Massachusetts General Hospital
Co-Leader, Lung Cancer Program, Dana Farber/Harvard Cancer Center

Charles Swanton, FRCP BSc PhD
’Tracking Lung Cancer Evolution: Insights from the TRACERx Program’
Chair, Personalised Cancer Medicine, University College London
Co-Director CR-UK UCL/Manchester Lung Cancer Centre of Excellence 
Translational Cancer Therapeutics Laboratory
Francis Crick Institute, London, UK

Marty Mayo, PhD
Role of Sirtuin 6 in lung cancer: friend or foe?
Professor, Biochemistry and Molecular Genetics
University of Virginia, School of Medicine
Department of Surgery
University of Virginia

Work in Progress Lectures


Goncalo Rodrigues, PhD
‘Exploring the role of tumor-derived exosomes in brain metastasis formation’
Weill Cornell Medicine

Joyce Chen, PhD
Weill Cornell Medical College, Cornell University

Piro Lito, MD PhD
Human Oncology & Pathogenesis Program

Thomas Reiner, PhD
Center for Molecular Imaging & Nanotechnology

Lee Jones, MD
Survivorship, Outcomes & Risk Program

Joan Massague, PhD
Director, Sloan Kettering Institute

Michael Berger, PhD
Associate Director, Center for Molecular Oncology


Yuan Liu, MD, PhD
Biochemist, Memorial Hospital Research Labs, David Jones Lab
’CK2α’ Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation’

Alex Drilon, MD
Thoracic Oncology Service
Romel Somwar, PhD
Department of Pathology
“Identifying Mechanisms of Acquired Resistance to RET Inhibition in RET-Rearranged Lung Cancers”

Natasha Rekhtman, MD, PhD
Department of Pathology
‘Genomic analysis of lung neuroendocrine tumors in the context of detailed histological, immunohistochemical and clinical correlation’

Paul Paik, MD
Clinical Director, Thoracic Oncology Service
‘A Phase 2 Study of MLN0128 in Patients with Advanced Squamous Cell Lung Cancers Harboring NFE2L2 and KEAP1 Mutations’

Benjamin Lok, MD
Molecular Pharmacology Program, Rudin Lab
‘Strategies to predict response to and maximize PARP inhibitor therapy for small cell lung cancer’

Hans Guido Wendel, MD
Member, Cancer Biology & Genetics Program, Center for Stem Cell Biology
J.T. Poirier, PhD
Thoracic Oncology Service, Molecular Pharmacology Program, Rudin Lab
‘eIF4A is a New Therapeutic Target in Small Cell Lung Cancer’

J.T. Poirier, PhD
Thoracic Oncology Service, Molecular Pharmacology Program, Rudin Lab
Jason Lewis, PhD
Chief, Radiochemistry and Imaging Sciences Services, Department of Radiology
‘Preclinical development of a DLL3-targeted theranostic for high-grade neuroendocrine lung cancers’

Eli Amin, PhD
Memorial Hospital Research Labs, David Jones Lab
‘ADAR mediated RNA editing in Lung Adenocarcinoma’

Joana DeCampos Vidigal, PhD
Cancer Biology & Genetics Program, Ventura Lab
‘Improving CRISPR-Cas9 tools for somatic genome editing’

Daniel Heller, PhD
Member, Molecular Pharmacology Program
‘Targeted Drug Delivery to the Tumor Microenvironment’

Prasad Adusumilli, MD
Deputy Chief, Translational and Clinical Research, Thoracic Surgery
‘CAR T-cell therapy for lung adenocarcinoma’

David R. Jones, MD
Director, DCLCR; Chief, Thoracic Surgery, Department of Surgery
‘The role of BRMS1 in p53 mutant lung adenocarcinoma’

Bob T. Li, MD
Thoracic Oncology Service
‘Circulating Tumor DNA in Lung Cancers - The State of the Art and the Future’

Eric Gardner, PharmD
Rudin Lab, Molecular Pharmacology Program
‘Chemo-sensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis”

Charles Rudin, MD, PhD
Director, DCLCR; Chief, Thoracic Oncology Service; Member, Molecular Pharmacology Program
‘New Targets in Small Cell Lung Cancer’